Inclusion Criteria:

- Acute Myeloid Leukemia (AML): all FAB subtypes except M3. Extent of disease:

- clinical remission after at least one course of polychemotherapy

- high risk of relapse due to age (> 60 years) or poor risk cytogenetic/molecular
markers or hyperleukocytosis at presentation or previous relapse

- Chronic myeloid leukemia (CML): patients in chronic phase under therapy with
tyrosinase kinase inhibitors who have sub-optimal response or failure and who are not
eligible for hematopoietic stem cell transplantation.

- Multiple Myeloma (MM): symptomatic with active disease, independent of earlier and/or
concomitant treatment:

- Presence of serum/urine M protein (> 3 g/dl)

- Bone marrow plasmacytosis (>10-30%)

- Anemia, renal failure, hypercalcemia, and/or lytic bone lesions

- Overexpression of WT1 RNA in peripheral blood and or bone marrow as assessed by
quantitative RT-PCR at the time of presentation.For CML: residual molecular disease
as demonstrated by BCR-ABL RT-PCR

- Prior treatments: Patients must have received at least one prior antileukemic
chemotherapeutic regimen and must be more than 1 month past the last treatment.

- Age: ≥ 18 years

- Performance status: WHO PS grade 0-1 (Appendix B)

- Objectively assessable parameters of life expectancy: more than 3 months

- Prior and concomitant associated diseases allowed with the exception of underlying
autoimmune disease and positive serology for HIV/HBV/HCV

- No concomitant use of immunosuppressive drugs

- adequate renal and liver function, i.e. creatinin and bilirubin = 1.2 times the upper
limit of normal

- absence of any psychological, familial, sociological or geographical condition
potentially hampering compliance with the study protocol and follow-up schedule;
those conditions should be discussed with the patient before registration in the
trial

- Women of child-bearing potential should use adequate contraception prior to study
entry and for the duration of study participation

Exclusion Criteria:

- Subjects with concurrent additional malignancy (with exception of non-melanoma skin
cancers and carcinoma in situ of the cervix)

- Subjects who are pregnant

- Subjects who have sensitivity to drugs that provide local anesthesia

- Subjects needing corticosteroids 1 mg/kg during vaccination; corticosteroids are
allowed as part of their treatment when taken ≥ 30 days before the start of
vaccination.